The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double‐blind, placebo‐controlled study, we tested the safety and efficacy of cilofexor (formerly GS‐9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhosis with large‐duct PSC. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Trauner, Michael, Gulamhusein, Aliya, Hameed, Bilal, Caldwell, Stephen, Shiffman, Mitchell L., Landis, Charles, Eksteen, Bertus, Agarwal, Kosh, Muir, Andrew, Rushbrook, Simon, Lu, Xiaomin, Xu, Jun, Chuang, Jen‐Chieh, Billin, Andrew N., Li, Georgia, Chung, Chuhan, Subramanian, G. Mani, Myers, Robert P., Bowlus, Christopher L., Kowdley, Kris V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767458/
https://www.ncbi.nlm.nih.gov/pubmed/30661255
http://dx.doi.org/10.1002/hep.30509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767458/
https://www.ncbi.nlm.nih.gov/pubmed/30661255
http://dx.doi.org/10.1002/hep.30509

Ejemplares similares